COMPASS Pathways plc 公布的数据表明,其研究性疗法COMP360继续展现出良好的耐受性与安全性特征,且未出现新的安全性发现。
COMPASS Pathways plc 公布的数据表明,其研究性疗法COMP360继续展现出良好的耐受性与安全性特征,且未出现新的安全性发现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.